dac-hyp Search Results


dac hyp  (AbbVie Inc)
90
AbbVie Inc dac hyp
Intracellular cytokine secretion of each research subject was analyzed for IFN-γ + , TNF-α + and double positive T cell events. The sums of all cytokine positive events were normalized to beads. Ratios of intrathecal to peripheral T cell reactivities of un-treated (RR) and <t>DAC</t> <t>HYP-treated</t> RRMS patients (Dac) were calculated to foreign Ag's for CD4 + ( A ) and CD8 + T cells ( B ). Ratios greater than one (dotted line) indicate enrichment of Ag-specific T cell events in the intrathecal compartment; ratios lower than one represent less pronounced intrathecal T cell responses. Horizontal bars represent median values; vertical lines represent interquartile ranges. *0.01<p<0.05, **0.001<p<0.01, ***p<0.001 .
Dac Hyp, supplied by AbbVie Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dac-hyp/dac+hyp/pmc04141762-63-16-20
Average 90 stars, based on 1 article reviews
dac hyp - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
dac hyp  (Biogen Inc)
86
Biogen Inc dac hyp
Intracellular cytokine secretion of each research subject was analyzed for IFN-γ + , TNF-α + and double positive T cell events. The sums of all cytokine positive events were normalized to beads. Ratios of intrathecal to peripheral T cell reactivities of un-treated (RR) and <t>DAC</t> <t>HYP-treated</t> RRMS patients (Dac) were calculated to foreign Ag's for CD4 + ( A ) and CD8 + T cells ( B ). Ratios greater than one (dotted line) indicate enrichment of Ag-specific T cell events in the intrathecal compartment; ratios lower than one represent less pronounced intrathecal T cell responses. Horizontal bars represent median values; vertical lines represent interquartile ranges. *0.01<p<0.05, **0.001<p<0.01, ***p<0.001 .
Dac Hyp, supplied by Biogen Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dac-hyp/dac+hyp/fda_document____drugsatfda_docs_slash_nda_slash_2016_slash_761029orig1s000otherr-949-5-14
Average 86 stars, based on 1 article reviews
dac hyp - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier

Image Search Results


Intracellular cytokine secretion of each research subject was analyzed for IFN-γ + , TNF-α + and double positive T cell events. The sums of all cytokine positive events were normalized to beads. Ratios of intrathecal to peripheral T cell reactivities of un-treated (RR) and DAC HYP-treated RRMS patients (Dac) were calculated to foreign Ag's for CD4 + ( A ) and CD8 + T cells ( B ). Ratios greater than one (dotted line) indicate enrichment of Ag-specific T cell events in the intrathecal compartment; ratios lower than one represent less pronounced intrathecal T cell responses. Horizontal bars represent median values; vertical lines represent interquartile ranges. *0.01<p<0.05, **0.001<p<0.01, ***p<0.001 .

Journal: PLoS ONE

Article Title: A Complex Role of Herpes Viruses in the Disease Process of Multiple Sclerosis

doi: 10.1371/journal.pone.0105434

Figure Lengend Snippet: Intracellular cytokine secretion of each research subject was analyzed for IFN-γ + , TNF-α + and double positive T cell events. The sums of all cytokine positive events were normalized to beads. Ratios of intrathecal to peripheral T cell reactivities of un-treated (RR) and DAC HYP-treated RRMS patients (Dac) were calculated to foreign Ag's for CD4 + ( A ) and CD8 + T cells ( B ). Ratios greater than one (dotted line) indicate enrichment of Ag-specific T cell events in the intrathecal compartment; ratios lower than one represent less pronounced intrathecal T cell responses. Horizontal bars represent median values; vertical lines represent interquartile ranges. *0.01

Article Snippet: In addition to the un-treated RRMS cohort, 19 RRMS patients received long-term treatment (>36 months) with DAC HYP (provided by AbbVie Biotherapeutics and Biogen Idec), a version of daclizumab under clinical trial evaluation (Clinicaltrials.gov identifier NCT01143441).

Techniques: